- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09:17 | TRANSTHERA-B Reverts Down 20% after Midday | 1 | AASTOCKS | ||
| 06:47 | TRANSTHERA-B Says Unaware of Reasons for Unusual Shr Price & Volume Changes | 1 | AASTOCKS | ||
| 06:17 | HSI Closes Midday at 26,466, Up 19 pts; HSTI Closes Midday at 6,067, Up 23 pts; CHINAHONGQIAO Down over 5%; NTES, HSBC HOLDINGS, BAYZED HEALTH, TRANSTHERA-B, BRAINAURORA-B Hit New Highs | 5 | AASTOCKS | ||
| 06:03 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS | 1 | HKEx | ||
| 05:17 | HSI Once Tops 26,600-mark to Hit 4-Yr High; Newcomers in Stock Connect Surge; BAYZED HEALTH, TRANSTHERA-B Soar 47-54% | 1 | AASTOCKS | ||
| 04:47 | TRANSTHERA-B Once Leaps 64% in Early Trading, Soaring 50x in Less Than 3 Mths Since Debut, Surpassing HANSOH PHARMA in Mkt Cap | 5 | AASTOCKS | ||
| 04:17 | TRANSTHERA-B Opens Up 15% to Hit New Highs, Surpassing SINO BIOPHARM, CSPC PHARMA in Mkt Cap w/35x Surge in Less Than 3 Mths Since Debut | 4 | AASTOCKS | ||
| Mo | HSI Closes at 26,446, Up 58 pts; HSTI Closes at 6,043, Up 54 pts; WUXI BIO Up over 6%; BABA, NONGFU SPRING, NTES, TRANSTHERA-B, BAYZED HEALTH Hit New Highs; Market Turnover Rises | 9 | AASTOCKS | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| Mo | HSI Closes Midday at 26,463, Up 75 pts; HSTI Closes Midday at 6,055, Up 66 pts; POP MART Down over 7%; BABA, NTES, BAYZED HEALTH, BRAINAURORA-B, TRANSTHERA-B Hit New Highs | 14 | AASTOCKS | ||
| Fr | TRANSTHERA-B Spikes ~1.2x w/Heavy Trading, Soars ~17x in Less Than 3 Mths since Listing | 3 | AASTOCKS | ||
| Do | HSI Closes at 26,086, Down 113 pts; HSTI Closes at 5,888, Down 13 pts; MEITUAN Down over 5%; WH GROUP, ZIJIN MINING, HSBC HOLDINGS, CHOW TAI FOOK, TRANSTHERA-B Hit New Highs; Market Turnover Rises | 6 | AASTOCKS | ||
| Mi | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PHASE II IND APPROVAL OF TINENGOTINIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF PREVIOUSLY TREATED ... | - | HKEx | ||
| 04.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH AKESO'S (CADONILIMAB, ... | - | HKEx | ||
| 25.08. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS A CONSTITUENT OF THE HANG SENG INDEX SERIES | 1 | HKEx | ||
| 25.08. | TRANSTHERA-B (02617): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | 1 | HKEx | ||
| 25.08. | TRANSTHERA-B (02617): CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | - | HKEx | ||
| 13.08. | TRANSTHERA-B (02617): DATE OF BOARD MEETING | - | HKEx | ||
| 04.08. | TRANSTHERA-B (02617): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 4 AUGUST 2025 | - | HKEx | ||
| 11.07. | TRANSTHERA-B (02617): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 4 AUGUST 2025 | 2 | HKEx | ||
| 11.07. | TRANSTHERA-B (02617): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
| APOGEE THERAPEUTICS | 36,860 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| IMMUNOVANT | 15,530 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCELLX | 75,20 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 36,210 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| BEAM THERAPEUTICS | 21,280 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 16,930 | 0,00 % | Arcutis bei H.C. Wainwright: Strategisches Wachstum und Pipeline-Entwicklung | ||
| AVIDITY BIOSCIENCES | 40,190 | 0,00 % | Avidity Biosciences schließt Kapitalerhöhung über 690 Millionen US-Dollar ab | ||
| CG ONCOLOGY | 34,600 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
| RAPPORT THERAPEUTICS | 24,730 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | ||
| TOURMALINE BIO | 47,650 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 6,930 | 0,00 % | Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa | DJ Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa
Von Adriano Marchese
DOW JONES--Novartis hat eine potenziell milliardenschwere Entwicklungspartnerschaft mit dem US-Biotechunternehmen... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,850 | 0,00 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,065 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,410 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report |
TRANSTHERA SCIENCES NANJING INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.